A Prospective Evaluation of Glucagon Stimulation Test Safety in Adults With Chronic Moderate‐to‐Severe Traumatic Brain Injury
Endocrinology, Diabetes & Metabolism · 2026-07 · 9 (4)
DOI: 10.1002/edm2.70260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 15.06.2026. Verfasst von Corey Snyder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liberty University College of Osteopathic Medicine, Lynchburg, Virginia, USA. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Glucagon, Human Growth Hormone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Growth hormone deficiency (GHD) is a common and clinically significant consequence of moderate‐to‐severe traumatic brain injury (msTBI). The glucagon stimulation test (GST) is widely used to assess growth hormone deficiency; however, the safety of GST has not been systematically evaluated in adults with chronic msTBI.
Methods
This prospective study enrolled 138 adults aged 18–65 years with chronic msTBI (≥ 1‐year post‐injury) from a single academic Brain Injury Center neuroendocrine registry. All participants underwent standardized GST with systematic symptom assessment at baseline and serial intervals over 240 min. Adverse events and symptoms were graded by severity using predefined clinical criteria, and participants were analysed by GHD status and by presence of any adverse event.
Results
GST was well tolerated, with no serious adverse events, test terminations, or prolonged sequelae. The most common adverse effect was nausea (30.4%), with vomiting in 9.4% of participants; antiemetics were required in 16.7% of cases. Female sex was significantly associated with nausea ( p < 0.001), while age and BMI were not. Neuroglycopenic symptoms occurred in 13% of participants and were mild to moderate; only two individuals (1.5%) required oral glucose rescue, and no severe neuroglycopenia occurred. Headache (12.3%), asthenia (10.1%), and mild symptomatic hypotension (2.9%) were infrequent. Adverse events typically occurred between 60 and 210 min and resolved within the 4 h testing period. There was no significant association between GHD status, peak GH concentration, or adjusted multivariable analysis and the occurrence of adverse events. No seizures occurred, including among participants with post‐traumatic epilepsy.
Conclusions
In adults with chronic msTBI, the glucagon stimulation test demonstrates a favourable safety profile with transient, non‐severe adverse effects and no serious neurological or metabolic complications. These findings support GST as a safe and practical method for evaluating growth hormone deficiency in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liberty University College of Osteopathic Medicine, Lynchburg, Virginia, USA.
- Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
- Edward Via College of Osteopathic Medicine, Blacksburg, Virginia, USA.
ORCID-Profile: Corey Snyder, Emily Hillaker, Justin Weppner
Zitieren
APA
Snyder, C., Hillaker, E., & Weppner, J. (2026). A Prospective Evaluation of Glucagon Stimulation Test Safety in Adults With Chronic Moderate‐to‐Severe Traumatic Brain Injury. Endocrinology, Diabetes & Metabolism, 9(4). https://doi.org/10.1002/edm2.70260
Vancouver
Snyder C, Hillaker E, Weppner J. A Prospective Evaluation of Glucagon Stimulation Test Safety in Adults With Chronic Moderate‐to‐Severe Traumatic Brain Injury. Endocrinology, Diabetes & Metabolism. 2026;9(4). doi:10.1002/edm2.70260
BibTeX
@article{Snyder2026,
author = {Snyder, Corey and Hillaker, Emily and Weppner, Justin},
title = {A Prospective Evaluation of Glucagon Stimulation Test Safety in Adults With Chronic Moderate‐to‐Severe Traumatic Brain Injury},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {4},
doi = {10.1002/edm2.70260}
}
EUVIMED